Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 14/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 3/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5043085 | 0.97 | NPC1 (0.41) | CD38NPC1RAB9AMMP1LIPG | |
| SCHEMBL5040906 | 0.94 | NPC1 (0.46) | CD38NPC1RAB9AMMP1 | |
| SCHEMBL5037996 | 0.94 | NPC1 (0.44) | CD38NPC1RAB9AMMP1 | |
| SCHEMBL5036523 | 0.93 | NPC1 (0.48) | CD38NPC1RAB9AMMP1 | |
| SCHEMBL7046162 | 0.85 | NPC1 (0.37) | CD38NPC1RAB9AMMP1LIPG | |
| SCHEMBL5037979 | 0.83 | NPC1 (0.43) | NPC1RAB9AMMP1CYP2D6 | |
| SCHEMBL5037717 | 0.83 | ENPP3 (0.45) | NPC1RAB9AMMP1 | |
| SCHEMBL5036028 | 0.83 | NPC1 (0.48) | NPC1RAB9A | |
| SCHEMBL5035937 | 0.83 | MET (0.43) | MMP1CYP2D6 | |
| SCHEMBL5040954 | 0.83 | MAPT (0.38) | MMP1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432417-B1 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | AVENTIS PHARMA SA (FR) | 2008-02-20 | — | — | EP | disclosed |
| US-7041668-B2 | Substituted benzimidazole compounds and their use for the treatment of cancer | AVENTIS PHARMA S.A. (FR) | 2006-05-09 | — | — | US | disclosed |
| US-20050014811-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | AVENTIS PHARMA S.A. (FR) | 2005-01-20 | — | — | US | disclosed |
| EP-1432417-A2 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | Aventis Pharma S.A. (FR) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003028721-A2 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | AVENTIS PHARMA S.A. (FR) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014811-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | CDKL3, CCNL2, CDKL1 | CD38 2389/4885NPC1 3782/4885RAB9A 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.